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OBJECTIVES: Doppler ultrasonography can be used to assess neoangiogenesis, a characteristic feature of
postmolar gestational trophoblastic neoplasia. However, there is limited information on whether uterine artery
Doppler flow velocimetry parameters can predict gestational trophoblastic neoplasia following a complete
hydatidiform mole. The purpose of this study was as follows: 1) to compare uterine blood flow before and after
complete mole evacuation between women who developed postmolar gestational trophoblastic neoplasia
and those who achieved spontaneous remission, 2) to assess the usefulness of uterine Doppler parameters as
predictors of postmolar gestational trophoblastic neoplasia and to determine the best parameters and cutoff
values for predicting postmolar gestational trophoblastic neoplasia.
METHODS: This prospective cohort study included 246 patients with a complete mole who were treated at three
different trophoblastic diseases centers between 2013 and 2014. The pulsatility index, resistivity index, and
systolic/diastolic ratio were measured by Doppler flow velocimetry before and 4-6 weeks after molar evacu-
ation. Statistical analysis was performed using Wilcoxon’s test, logistic regression, and ROC analysis.
RESULTS: No differences in pre- and post-evacuation Doppler measurements were observed in patients who
developed postmolar gestational trophoblastic neoplasia. In those with spontaneous remission, the pulsatility
index and systolic/diastolic ratio were increased after evacuation. The pre- and post-evacuation pulsatility
indices were significantly lower in patients with gestational trophoblastic neoplasia (odds ratio of 13.9-30.5).
A pre-evacuation pulsatility index p1.38 (77% sensitivity and 82% specificity) and post-evacuation pulsatility
index p1.77 (79% sensitivity and 86% specificity) were significantly predictive of gestational trophoblastic
neoplasia.
CONCLUSIONS: Uterine Doppler flow velocimetry measurements, particularly pre- and post-molar evacuation
pulsatility indices, can be useful for predicting postmolar gestational trophoblastic neoplasia.
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’ INTRODUCTION
A complete hydatidiform mole (CHM), which is char-
acterized by increased hyperplasia, progresses to gestational
trophoblastic neoplasia (GTN) in 9-20% of cases (1). Suction
curettage is the method of choice for CHM evacuation.
During CHM follow-up, serial assessment of serum human
chorionic gonadotropin (hCG) is the standard method to
identify postmolar malignancy. A rise or plateau in hCG indi-
cates the likely onset of malignancy requiring chemotherapy.
Predicting CHM malignancy potential is of the utmost
importance because it allows for the prompt treatment of
post-molar GTN, limiting the exposure of most patients to
combination chemotherapy (2). Moreover, predicting CHM
malignant potential can help in selecting the patients whoDOI: 10.6061/clinics/2017(05)05
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may benefit from prophylactic chemotherapy, particularly
when close hCG follow-up is not possible.
Clinical factors, such as age, ovarian enlargement, a large-
for-date uterus, previous history of molar pregnancy, hCG
level (3,4), and expression of endocrine gland-derived vas-
cular endothelial growth factor (EG-VEGF), HIF-1alpha, and
TGF- beta 3 have all been reported to be helpful in predicting
post-CHM GTN (5,6).
Transvaginal ultrasound with power Doppler can predict
delayed response to chemotherapy and drug resistance in
low-risk trophoblastic neoplasia (7). Doppler US of the
pelvis, an important tool in the diagnosis of GTN (8,9), is also
used as part of GTN routine staging to assess the uterine
volume and blood flow. Changes in flow resistance can relia-
bly determine the appropriate chemotherapeutic regimen for
GTN as well as predict the GTN response to chemotherapy
(10,11). Moreover, the highly abnormal flow patterns seen in
invasive gestational trophoblastic neoplasia can be measured
by Doppler US as early as two weeks post-evacuation, which
is before the appearance of lesions (12) or an hCG plateau or
rise (10). However, it remains controversial whether uterine
artery Doppler flow velocimetry (DFV) parameters can
predict GTN following CHM (13).
The purpose of this study was two-fold and is summar-
ized as follows: 1) to compare uterine blood flow before and
after CHM evacuation between women with post-molar
GTN and those with spontaneous remission 2) to assess the
usefulness of uterine DFV parameters as predictors of post-
CHM GTN and determine the best prediction parameters
and cutoffs.
’ METHODS
This prospective cohort study included women with CHM
who were treated at three different trophoblastic diseases
centers between 2013 and 2014. CHM was diagnosed based
on ultrasound findings confirmed by histopathological anal-
ysis and p57 immunohistochemistry. All patients were ini-
tially treated with suction D&C, and they underwent uterine
artery Doppler flow velocimetry (DFV) at admission and after
CHM evacuation. Women were excluded from the study if
they did not undergo post-evacuation DFV or were lost to
follow-up after this procedure. The study was approved by
the Institutional Committee of Research Ethics (August 8,
2013, #15983613.8.0000.5411), and it was conducted in accor-
dance with the Declaration of Helsinki. Written informed con-
sent was obtained from all patients.
Assuming that GTN follows CHM in 15% of cases, the
minimum sample size was estimated to be 175 patients (type
1 error = 0.05 and type 2 error = 0.20) to achieve a statistical
power of 0.8 (80%) in all tests.
Data collected at admission included age, number of pre-
gnancies, parity, gestational age at diagnosis, uterine size,
presence of theca lutein cysts 46 cm (indicative of higher
risk of malignancy), and pre-evacuation hCG level. An exces-
sive uterine size was considered present if the uterus was at
least 4 weeks greater in size than expected for the gestational
age on clinical examination (14,15). Theca lutein ovarian
cysts 46 cm were identified by pelvic ultrasound and by
bimanual pelvic examination performed under anesthesia
prior to uterine evacuation (14).
Transabdominal sonography was performed for global eval-
uation of the pelvis, and transvaginal imaging was performed
for a more detailed evaluation of the uterus, endometrial
cavity and adnexae. Because the site of molar implantation in
the uterus was unknown, the DFVof both uterine arteries was
performed at admission (up to 2 hours pre-evacuation) and
4-6 weeks after CHM evacuation. Doppler assessments were
performed using a Colored Doppler Ultrasound (Power Vision
6000 TOSHIBAs, New York, NY, USA) with a 5.0-MHz con-
vex transducer. For the transvaginal scan, women were
asked to empty their bladders and were placed in the dorsal
lithotomy position. The ultrasound probe was then inser-
ted into the vagina and placed in the lateral fornix, and the
uterine artery was identified using color Doppler at the level
of the internal cervical os. The ascending branch of the uter-
ine artery at both its paracervical portion and at the point
closest to the internal os was identified, and pulsed wave
Doppler was applied with the sampling gate set at 2 mm at
an angle of insonation o30o. After four consecutive similar
waveforms were obtained, the pulsatility index (PI), resis-
tivity index (RI), and systolic/diastolic ratio (S/D) were
automatically calculated by the scanner software. The PI, RI





A= peak systolic velocity
B= end diastolic velocity
Mean= mean velocity
Post-molar GTN was diagnosed according to the follow-
ing criteria standardized by the International Federation of
Gynecology and Obstetrics (FIGO 2002) (16):
(1) An hCG level plateau of four values ±10% recorded
over a 3-week duration (days 1, 7, 14, and 21).
(2) An hCG level increase of more than 10% of three values
recorded over a 2-week duration (days 1, 7, and 14).
Remission was declared after undetectable hCG levels
were achieved for 3 consecutive weeks and then at monthly
intervals for 1 year.
Statistical analyses were performed using SPSS v 21.0(IBM
Corp, Armonk, NY, USA). The non-parametric Wilcoxon test
was used to compare pre- and post- CHM evacuation DFV
parameters between women who developed post-molar GTN
and those who achieved spontaneous remission. The useful-
ness of uterine DFV parameters as predictors of post-CHM
GTN was assessed using multiple logistic regression adjusted
for age, gestational age, enlarged uterus for gestational age,
theca lutein cysts, and pre-evacuation hCG level. The best
DFV parameters and cutoff values for predicting post-CHM
GTN were determined by receiver operating characteristic
(ROC) analysis, including calculation of the areas under the
curves. Statistical significance was set at po0.05.
’ RESULTS
Of 276 women diagnosed with CHM, 246 were included in
the analysis. Of the 30 remaining women, 17 did not undergo
post-evacuation DFV, and 13 were lost to follow-up after
post-evacuation DFV; therefore, they were excluded from the
study. The median patient age was 24 years (13-47 years),
and the median gestational age was 8 weeks (4-16 weeks).
No significant differences were observed between pre- and
post-evacuation or right and left uterine artery DFV mea-
surements. Development into GTN occurred in 20% of the
cases (Table 1).
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Table 2 shows that, compared to the pre-evacuation mea-
surements, the PI and S/D significantly increased in both
arteries, while the RI remained unchanged after evacuation
in women with spontaneous remission. In those who devel-
oped GTN, the DFV measurements remained unchanged
pre- and post-evacuation.
PI was the Doppler parameter that was most strongly
associated with risk of post-CHM GTN both pre-and post-
evacuation, i.e., women showing lower PI values were more
likely to develop GTN following CHM (OR 13.9-30.5, 95%
CI = 5.97 – 32.60 and 12.01 – 77.52, respectively) (Table 3).
The best PI cutoff points for predicting GTN were p1.38
pre-evacuation (77% sensitivity and 82% specificity; 95%
CI 0.72 – 0.86) and p1.77 post-evacuation (79% sensitivity
and 86% specificity; 95% CI 0.77 – 0.91) (Table 4).
’ DISCUSSION
Neoangiogenesis is a critical feature of malignancy. It is a
key component of tumorigenesis, tumor growth and meta-
static spread, and it is associated with drug resistance and
poor prognosis in several solid tumors (11,17).
Doppler flow velocimetry (DFV) offers a noninvasive tech-
nique for neoangiogenesis quantification by assessing the
vascularity and circulatory resistance of blood flow through
the uterine arteries. In the early diagnosis of invasive GTD,
DFV clearly shows an advantage over classical hCG measure-
ments because it can detect the presence of post-evacuation
invasive GTD weeks before an hCG rise or plateau occurs
(10,18). Doppler uterine artery PI is inversely proportional to
tumor vascularity, and a low uterine artery PI indicates increa-
sed arteriovenous shunting (11), a feature that leads to large
low-resistance blood vessels, an inherent characteristic of tro-
phoblastic invasion.
Our results show that most women participating in this
study were young (13-47 years) and were diagnosed in the early
first trimester of pregnancy. The development of post-CHM
GTN occurred in 20% of the cases; this rate is similar to those
found in studies that include patients diagnosed later in the first
trimester or even in the second trimester of pregnancy (19-21).
This indicates that the gestational age at diagnosis does not
affect the risk of developing postmolar GTN, as demonstrated
by others (15,22,23).
Compared to pre-evacuation measurements, the PI and
S/D significantly increased (in both arteries) after evacua-
tion in participants with spontaneous remission (n=197). In
those who developed GTN, the pre- and post-evacuation
Table 3 - Multiple logistic regression of the usefulness of each
uterine DFV parameter as a predictor of gestational
trophoblastic neoplasia following development of a complete
hydatidiform mole, adjusted for age, gestational age, size uterus
4 date, theca lutein cysts, and pre-evacuation hCG level.
Side: Time: Index p OR (95% CI)
Right, Pre-evacuation, PI 0.0000 19.87 (7.60 – 51.91)
Right, Pre-evacuation, RI 0.0480 11.48 (1.02 – 129.26)
Right, Pre-evacuation, S/D 0.0060 1.27 (1.07 – 1.51)
Left, Pre-evacuation, PI 0.0000 13.96 (5.97 – 32.60)
Left, Pre-evacuation, RI 0.3380 2.87 (0.33 – 24.83)
Left, Pre-evacuation, S/D 0.9510 1.00 (0.88 – 1.14)
Right, Post-evacuation, PI 0.0000 16.25 (7.25 – 36.44)
Right, Post-evacuation, RI 0.0430 13.29 (1.08 – 163.54)
Right, Post-evacuation, S/D 0.0760 1.13 (0.98 – 1.29)
Left, Post-evacuation, PI 0.0000 30.51 (12.01 – 77.52)
Left, Post-evacuation, RI 0.0170 24.23 (1.75 – 334.80)
Left, Post-evacuation, S/D 0.1670 0.95 (0.88 – 1.02)
Table 1 - Patient characteristics (n = 246) and pre- and post-
evacuation uterine artery DFV measurements.
Variable
Age (years) (1) 24 (13 – 47)
Gravidity (1) 2 (1 – 16)
Parity (1) 0 (0 – 8)
Gestational age (weeks) (1) 8 (4 – 16)
Uterine Size 4 gestational age 58 (24%)
Theca lutein cysts 26 (11%)
Pre-evacuation hCG (mUI/mL) (1) 53171 (382 – 2842101)
Right, Pre-evacuation, PI (1) 1.83 (0.73 – 3.34)
Right, Pre-evacuation, RI (1) 0.82 (0.43 – 3.40)
Right, Pre-evacuation, S/D (1) 4.80 (1.88 – 16.40)
Left, Pre-evacuation, PI (1) 1.78 (0.75 – 3.09)
Left, Pre-evacuation, RI (1) 0.82 (0.43 – 1.82)
Left, Pre-evacuation, S/D (1) 4.40 (1.70 – 17.00)
Right, Post-evacuation, PI (1) 2.02 (0.55 – 6.05)
Right, Post-evacuation, RI (1) 0.82 (0.39 – 2.49)
Right, Post-evacuation, S/D (1) 5.90 (1.20 – 19.20)
Left, Post-evacuation, PI (1) 1.94 (0.56 – 4.06)
Left, Post-evacuation, RI (1) 0.83 (0.36 – 0.99)
Left, Post-evacuation, S/D (1) 5.53 (1.68 – 37.10)
Postmolar GTN 49 (20%)
(1)Median (minimum-maximum)
Table 2 - Pre- and post-evacuation uterine artery Doppler flow velocimetry in women who achieved spontaneous remission and those
who developed GTN.
Spontaneous remission (n=197) GTN (n=49)
Pre Post p(1) Pre Post p(1)
Right, PI 1.87 2.12 o0.001 1.13 1.10 0.778
(0.73 - 3.34) (0.55 - 5.24) (0.77 - 2.36) (0.62 - 6.05)
Right, RI 0.82 0.83 0.648 0.79 0.78 0.536
(0.47 - 3.40) (0.39 - 2.49) (0.43 - 0.92) (0.43 - 1.12)
Right, S/D 4.76 5.9 o0.001 4.9 4.89 0.045
(1.88 - 16.40) (1.88 - 19.20) (2.12 - 12.38) (1.20 - 12.7)
Left, PI 1.89 1.97 o0.001 1.16 1.20 0.375
(0.75 - 3.09) (0.68 - 4.06) (0.80 - 2.95) (0.56 - 3.29)
Left, RI 0.82 0.83 0.236 0.81 0.78 0.186
(0.43 - 1.82) (0.41 - 0.99) (0.52 - 0.98) (0.36 - 0.98)
Left, S/D 4.28 5.5 o0.001 5.8 5.80 0.984
(1.75 - 17.00) (1.68 - 13.08) (1.70 - 12.5) (1.81 - 37.1)
(1)Wilcoxon. Median (minimum-maximum)
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DFV measurements remained (n=49) significantly lower.
Similar findings (15,18,24,25) have been reported in smaller
patient populations. Yalcin et al. (18) found that significantly
lower uterine artery Doppler indices before molar evacuation
were associated with the development of GTN in 5 com-
pared with 16 patients with spontaneous remission. Simi-
larly, Gungor et al. (26) reported a lower uterine artery RI
before molar evacuation in 12 patients who developed per-
sistent malignant disease compared with 20 patients who
had spontaneous remission. In contrast, the study by Chan
et al. (27) showed no difference in RI in 11 patients with
spontaneous remission compared with 21 patients with post-
molar persistent disease.
In this study, PI was the Doppler parameter that was most
strongly associated with the risk of post-CHM GTN pre-
and post-evacuation. The best cutoff PI values for predicting
GTN were p1.3 pre-evacuation (77% sensitivity, 82% speci-
ficity) and p1.7 post-evacuation (79% sensitivity, 86% speci-
ficity). These values are similar to those reported by Maymon
et al. (12), who observed that PI levels p1.5 predicted GTN
in the 2nd post-evacuation week. Notably, a cutoff p1.1 has
been associated with chemoresistance in trophoblastic tumors
(11,28-30). The high sensitivity and specificity values obtained
in this study support the theory that DFV measurements can
identify those patients at a higher risk of developing GTN
after CHM.
Previous studies assessing the role of Doppler indices in
predicting the development of trophoblastic tumors have
yielded conflicting findings, which is probably because of
the small number of patients. The results of this larger
prospective study show that uterine DFV measurements,
particularly pre- and post-molar evacuation PI, can be useful
for predicting GTN following CHM in a much larger popu-
lation. Indeed, participants with lower PI values were more
likely to develop GTN following CHM. However, although
the Doppler angle of insonation was kept as low as possible,
small deviations and inaccuracies in drawing the contour
of the waves may have occurred due to the small diameter
and tortuosity seen in the uterine vessels. Nonetheless, the
uterine artery PI has been considered an objective measure
of vascularity that is not based on the subjective selection
of regions of interest, and it has been reported as a useful
noninvasive marker of tumor vascularity in previous studies
(11,29). Interestingly, in other gynecologic conditions, such as
endometrial lesions and adnexal masses (31,32), the uterine
artery PI has also been used for differentiating between benign
and malignant tumors.
Predicting a high chance for developing GTN has become
highly important as the early detection of molar pregnancy
with ultrasound no longer allows for observation of some
clinical features, such as theca lutein cysts and large-for-age
uterine size, which are only encountered at a more advanced
gestational age (25). Furthermore, hCG testing cannot detect
the patients who are more likely to develop GTN in the first
weeks after evacuation (25).
It is noteworthy, however, that, according to Kohorn (33),
the use of ultrasound or DFV to follow hydatidiform mole
regression is clinically and fiscally counterproductive. Never-
theless, several studies have demonstrated that changes in
Doppler indices inversely correlate with hCG titers and that
ultrasound can accurately identify patients who are at a
high risk for post-evacuation GTN when hCG levels are not
helpful (15,18,24,25,34). Because serial hCG assessment can-
not detect GTN in the first three weeks (25), it can delay
diagnosis, which has been associated with an increased FIGO
risk score (25) and greater chance of resistant disease (35).
The cost-effectiveness of ultrasound technologies has become
widely recognized. Moreover, as each one-point increment
in the FIGO score is associated with an average increase of
17 days in hCG remission time (36), the early detection of GTN
may decrease the economic and social burden of the disease.
In brief, this study demonstrated the following: 1) post-
evacuation DFV parameters were significantly increased
(in both arteries) in women with spontaneous remission, 2)
lower PI values were associated with a higher risk of devel-
oping GTN following CHM, and 3) PI was the Doppler
parameter most strongly associated with risk of post-CHM
GTN with cutoffs of p1.3 pre-evacuation and p1.7 post-
evacuation. These results, which were prospectively obtained
in a large population, validate the usefulness of the uterine
artery PI as a marker of GTN development following CHM.
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